Allison DeAngelis is a reporter at STAT, specializing in biotech and biopharma startups, as well as venture capital. She covers a range of topics within medicine and healthcare, including gene therapy, pharmaceutical manufacturing, and immunotherapy. Allison has been featured in The Boston Globe, STAT News, and RamaOnHealthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Allison Deangelis focuses on the healthcare and pharmaceutical industry, particularly biotechnology. Her articles often include press releases, private sector announcements, data citations, and expert commentary.
To effectively reach out to Allison Deangelis, consider providing insights or access to individuals with expertise in cutting-edge biotechnological developments such as gene therapy, novel drug discoveries for conditions like obesity or cancer treatment. Pitches could also involve exclusive interviews with key figures in startups and established companies within the biotech space.
As Allison's geographic focus is not specified but her coverage seems international in nature due to its emphasis on major industry events and global players within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Latus Bio plans to seek FDA permission to start the clinical trial in the next few months
By: Adam Feuerstein, Allison DeAngelis, Elaine Chen
On this week's episode of “The Readout LOUD,” we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech's successful IPO.
By: Allison DeAngelis
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company's first CAR-T candidates through human trials.
By: Allison DeAngelis, Adam Feuerstein, Elaine Chen
This week's episode of “The Readout LOUD” is all about health politics.
By: Allison DeAngelis, Matthew Herper
Report by UKlooks at progress on ‘innovation' and ‘invention' Here's one more sign of Eli Lilly's dominance in the drug industry: It took both top spots in a prominent ranking of pharmaceutical innovators and investors.
By: Allison DeAngelis, Elaine Chen, Adam Feuerstein
On this week's episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conversations and insights, including BridgeBio CEO Neil Kumar's comments that the company is publishing “not the right structures” in their research publications.
By: Allison DeAngelis
Retro Biosciences , the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday.
By: Elaine Chen, Allison DeAngelis, Adam Feuerstein
On this week's episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving
By: Elaine Chen, Allison Deangelis, Adam Feuerstein
Biotech is producing scientific breakthroughs that once seemed impossible. But according to longtime industry executive Jeremy Levin, the institutions
